[["index.html", "", "     II (ADME  )  (PIPET), AIMS BioScience, Q-fitter - Ver 0.0.1 (2022-06-03) 2022-09-14    ·    (pharmacokinetics)     .               .         ,      .                      .           ,          .              .       (,  )    ,           ,       .                            .       ,                 ,          .    20                    ,    . 1               .                            .      ,      , ,   ,            .                  .      ,                 .   /     ,       .          pdf   . 2  print on demand       /   .                 .      ,                   . 2022 9,      http://pipetlms.or.kr http://pipet.or.kr/books/pharmapk "],[".html", "Chapter 1  1.1  1.2    1.3     1.4 ", " Chapter 1   1.1  (solubility)             .              (disintegration), (dissolution)  (diffusion)      ( 1.1).  1.1:    (Di and Kerns 2015)      ,      .       ,            . ,          (Ficks law  1). ,              .            .     ,   PK       in vitro assay    in vivo        .  ,    in vitro assay buffer media               .   in vivo               clear solution    PK          .         ,     ,              . 1.2         ?       ?          .     (Permeability),      ,                 .           . Drug discovery           ( 1.1).  1.1: Drug discovery     Solubility (g/mL) Criteria &lt;10 Low 10-60 Moderate &gt;60 High Drug development    USP       .  ,       20±5 5 30     30    ,  1 g  1 mL            ( 1.2).  1.2:   USP      USP   1g  1 mL        Very soluble 1 mL    Freely soluble 1 mL  10 mL   Soluble 10 mL  30 mL    Sparingly soluble 30 mL  100 mL    Slightly soluble 100 mL  1000 mL     Very slightly soluble 1000 mL  10000 mL     Practically soluble 10000 mL         Biopharmaceutics Classification System (BCS)   ( 1.2).        4 class   . Class I:  ,   Class II:  ,   Class III:  ,   Class IV:  ,   Class I Class III     37  pH 1.2-6.8  1   () 30      250 mL   .   250 mL              .  1.2: Biopharmaceutics Classification System (BCS) 1.3     1.3.1         .      ,        .           .           .     ,        pKa   pH      .         .  (,     )       (Lipophilicity): LogP  LogD  (Ionizability): pKa 1.3.2            . ,        ,           .          .        .     pH   Compendial media  Bio-relevant media        ( pH  (pH 1.4-8.0),   )     ,     .        ,          .       Compendial media  Bio-relevant media      . 1.3.2.1 Compendial media   pH 1.0-3.0    (pepsin) ,   pH 5.7-7.7    (pancreatin) . Compendial media  pH     .   compendial media USP     ,           ( 1.3).  compendial media    , , ,           .  1.3:          (SGF, Stimulated Gastric Fluid)   (SIF, Stimulated Gastric Fluid)  USP       USP       pH 1.2 6.7   Pepsin, HCl, NaCl, water Pancreatin, KH2PO4, NaOH, water 1.3.3 Bio-relevant media Bio-relevant media compendial media   , , ,                 .          4   ( 1.4). FaSSGF (Fasted state Stimulated Gastric Fluid):        (Bile acid)   (Phospholipid)  . FeSSGF (Fed state Stimulated Gastric Fluid):    .              ,      pH             .          whole milk  Ensure® Plus   . FaSSIF (Fasted state Stimulated Intestinal Fluid):    ,       . FeSSIF (Fed state Stimulated Intestinal Fluid):    .      pH ,            .       mixed micelles    (Solubilization)   .  1.4: Compendial Media  Bio-relevant Media  Parameters Compendial Media Bio-relevant Media SGF SIF FaSSGF FeSSGF FaSSIF FeSSIF Osmolality (mOsmol/kg) Cannot mimic the GI tracts 120.7 - ~270 ~670 Buffer capacity (mEq/pH/L) - - ~12 ~72 Surface tension (mN/m) 42.6 - 54 48 Ion strength Can mimic the GI tracts Viscosity Food condition Fasted Fasted Fasted Fed Fasted Fed pH 1.2 6.8 1.6 3-6 or neutral 6.5 5.0 Composition Enzyme Pepsin Pancreatin Pepsin Pepsin Pancreatin Pancreatin Bile acid N.A. N.A.     Phospholipid N.A. N.A.     1.3.4          .             .    Kinetic solubility Thermodynamic solubility   . 1.3.4.1 Kinetic solubility Kinetic solubility DMSO      ,  buffer       .             Drug discovery    .   1.3      stock solution  buffer   in vitro    , Kinetic solubility   in vitro assay      .  1.3: Kinetic solubility         Nephelometry, Turbidimetry  Direct measurement  ( 1.5).      ,        ,      Nephelometry.          ,     Turbidimetry.  Direct measurement UV          UV      .  1.5: Kinetic solubility    Nephelometry Turbidimetry Direct measurement 1.3.4.2 Thermodynamic solubility Thermodynamic solubility         ,        ( 1.4).  Thermodynamic solubility Equilibrium solubility .    gold standard   ,  Drug development  .     24         ,      .  1.4: Thermodynamic solubility   Thermodynamic solubility            .  Kinetic solubility           ,        ( 1.5). Thermodynamic solubility Kinetic solubility       ,    (Polymorphism)  (Crystal form) .   Kinetic solubility      (Amorphous form)  .              .  1.5: Kinetic solubility Thermodynamic solubility  1.4   ADME : Physicochemical properties   .           , in vitro/in vivo            .                 .    highly potent   ,  lipophilicity            .  , , pH buffer, compendial  bio-relevant media          ,     .  (:          .) Edward H. Kerns and Li Di, Drug-like properties: Concepts, Structure Design and Methods. Lubrizol Life Science, Biopharmaceutical Classification System, 2019 https://3ehzg6104228bwtte1se19g6-wpengine.netdna-ssl.com/wp-content/uploads/2019/10/TB-28-Biopharmaceutical-Classification-System.pdf Everything you need to know about ADME, 3rd Edition, Cyprotex Alskär, L. C. et al., Improved molecular understanding of lipid-based formulations, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 262, 2018. Eleni Rinaki et al., Pharmaceutical Research, 20(12), 2003. Sandra Klein et al., The AAPS Journal, 12(3), 2010. Mark G. Papich and Marilyn N. Martinez, The AAPS Journal, 2015. Edward H. Kerns et al., Current Drug Metabolism, 9, 879-885, 2008. M9 Biopharmaceutics classification system based biowaivers, 2018. Jochen Maas et al., European Journal of Pharmaceutics and Biopharmaceutics, 66, 1-10, 2007. Prachi Shekhawat and Varsha Pokharkar, Acta Pharmaceutica Sinica B, 2016.  "],[".html", "Chapter 2  2.1  2.2   2.3    2.4       2.5     2.6 ", " Chapter 2   2.1   (Permeability)      .     ,            . , ,                ,       .   , , ,               ( 2.1).  2.1:              ,                       . 2.2   2.2.1         (phospholipid bilayer)  ,     ,          ( 2.2).  2.2:  :                 .    brush border    ,       (basolateral membrane)   .  transcellular        (passive transport)    (carrier), ,           (active transport)   .    (tight junction)  paracellular     ( 2.3).       ,       .               ,            .  2.3:    2.2.2                   .           ,   pKa    pH      .  soluble           .        ,    uptake  efflux transporter        (affinity)      ( 2.4).        . High lipophilicity Low ionizability High solubility High affinity to the uptake transporters Low affinity to the efflux transporters  2.4:      2.3    2.3.1 PAMPA (Parallel Artificial Membrane Permeability Assay)   ,           .              ,             PAMPA    . PAMPA   2.5    Kit  .  2.5: PAMPA    DMSO      stock solution .  Donor plate well      PBS buffer    , Acceptor plate well PBS buffer  25 C 5    Donor  Acceptor plate   LC-MS/MS        Pe . \\[\\begin{equation} P_{e} = C\\ \\times \\left\\lbrack - Ln\\mspace{6mu}\\left( 1 - \\frac{\\lbrack drug\\rbrack_{acceptor}}{\\lbrack drug\\rbrack_{equilibrium}} \\right) \\right\\rbrack \\tag{2.1} \\end{equation}\\] [drug]equilibrium = [drug]donor VD + [drug]acceptor x VA / (VD + VA) C = VD × VA / (VD + VA) × t × A VD = volume of donor compartment VA = volume of acceptor compartment A = filter area t = incubation time (in seconds) [drug]acceptor = Concentration of compound in the acceptor compartment at the assay completion [drug]donor = Concentration of compound in the donor compartment at the assay completion [drug]equilibrium = Concentration of compound at theoretical equilibrium      ,   UV plate reader           PAMPA      .     (cell-based assay)     pH   ,       .   PAMPA-BBB  Brain-Blood Barrier      . ,  UV plate reader         ,           .                transporter        . 2.3.2 Caco-2 cell-based permeability assay     Caco-2   , Caco-2           (: microvilli  tight junction )         . Caco-2    2.6   , well plate monolayer Caco-2  , Apical  Basolateral side          Apical  Basolateral side    .  2.6: Caco-2 cell-based permeability assay          (Papp, Apparent permeability coefficient)  Efflux ratio . \\[\\begin{equation} P_{app} = \\frac{\\frac{dQ}{dt}}{A \\cdot C_0} \\\\ Efflux\\ ratio = \\frac{P_{app (B to A)}}{P_{app (A to B)}} \\tag{2.2} \\end{equation}\\]  dQ/dt     (initial transport rate, mol/s), A well  (the surface area of the monolayer, cm2), C0    (initial concentration in the donor chamber, mol/cm3) . Caco-2             ,  (Apical membrane)   (Basolateral membrane)     .         P-glycoprotein (P-gp)  Breast cancer resistant protein (BCRP)  efflux transporter      (  Efflux ratio &gt; 2).     3  ,  1  antibiotics-free media    contamination                 .  Caco-2              . 2.3.3 MDCK cell-based permeability assay    MDCK (Madin-Darby Canine Kidney)   ,   tight junction   cell monolayer   . Caco-2      , efflux transporter     .  Caco-2    ,  3~4  cell monolayer       .   transporter     transporter      (transfected cell line)   .        transporter          (: MDCK II-MDR1 cell line).  2.7: MDCK cell-based permeability assay  2.1:        PAMPA Caco-2 cell-based MDCK cell-based Cell origin Artificial membrane Human colorectal carcinoma cells Madin-Darby canine kidney strain cells Cell morphology - Intestinal epithelium Distal tubule epithelium Cell growing time - &gt; 21 days 3~4 days Permeation mechanisms Passive diffusion Passive diffusion, Active transport, Paracellular and Efflux Direction of transport One-way (Donor  Acceptor) B i-directional (Apical  Basolateral) Expression of transporters Uptake transporters Not expressed OATP1B1, OATP1B3, OATP2B1, PepT1, OCT1, OCT2 and OCT3 OCT2, peptide and m onocarboxylic acids Efflux transporters Not expressed P-gp (MDR1), MRP2, MRP4 and BCRP P-gp (MDR1), MRP1, MRP2 and MRP5 Metabolism No Yes Yes -: not applicable. 2.4         in vitro         ,         .  in vitro                .        (drug discovery)      .  Caco-2                ( 2.8). FDA   (Biopharmaceutics Classification System, BCS) 6 ,                    Caco-2         .  Caco-2       (absorption rate constant, ka)     .  2.8: Caco-2        PAMPA             .     , PAMPA     (Pe) 10*10-6 cm/sec       .  Pe  10*10-6 cm/sec         , 1*10-6 cm/sec          . Caco-2   Apical to Basolateral    (Papp, A to B)       (reference drug)           .      FDA    ,     (fraction of human intestinal absorption; fa)  high (85%), moderate (50 - 84%), low (&lt;50%)  zero-permeable   .         high  low-permeable   1      .   ,      efflux ratio 2       efflux transporter   .   efflux transporter  ,   transporter               .   2.2  , P-gp     P-gp  Talinolol  Verapamil      .    Test drug A  P-gp  Talinolol   .  efflux ratio 2   Verapamil    apical to basolateral  Papp  2      .      efflux ratio 44.4    2  .  Test drug A P-gp   .  Test drug B efflux ratio  2 ,     Papp  efflux ratio     .  Test drug B P-gp  , P-gp  Caco-2    efflux transporter    .  2.2: Caco-2   P-gp    Without Verapamil (P-gp inhibitor) With Verapamil (P-gp inhibitor) Compound Papp (A to B) [x10-6 cm/sec] Papp (B to A) [x10-6 cm/sec] Efflux ratio Papp (A to B) [x10-6 cm/sec] Papp (B to A) [x10-6 cm/sec] Efflux ratio Talinolol (P-gp substrate) 0.292 11.5 39.3 1.07 1.34 1.25 Test drug A 0.397 40.1 101 0.959 42.6 44.4 Test drug B 12.6 22.5 1.78 11.8 24.3 2.05 Papp (A to B): permeability coefficient in apical to basolateral direction, Papp (B to A): permeability coefficient in basolateral to apical direction. 2.5            ,                  . \\[\\begin{equation} \\mathbf{Recovery\\ }\\left( \\mathbf{\\%} \\right) = \\frac{total\\ compound\\ in\\ both\\ of\\ A/B\\ sides\\ at\\ the\\ end\\ of\\ experiment\\ (nmol)}{initial\\ compound\\ present\\ (nmol)}\\ \\times \\ 100 \\\\ A:\\ apical,\\ B:\\ basolateral \\tag{2.3} \\end{equation}\\]            low-permeable      ,                     .   75%             ,         . Non-specific binding of test compound to plastic material Poor solubility of test compound in the media Instability of test compound in the media (i.e., due to the metabolism in cell) Accumulation of test compound in the cell monolayer        plastic ware  (non-specific binding)    bovine serum   plastic  bovine serum       plastic material     wash out         . 2.6   ADME : physicochemical properties   .        ,            .       efflux transporter      .        in vitro  ,       ,        .          ,      .  (:          .)  .     I (2021). .  :  3 (2005). Di, Li, and Edward Kerns. Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization. Academic press (2015). Cyprotex Ltd. Everything you need to know about ADME, 3rd Edition (2017). Volpe, Donna A. \"Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.\" Future medicinal chemistry 3.16 (2011): 2063-2077. ICH Harmonised Guideline, M9 Biopharmaceutics Classification System-Based Biowaivers (2018). Saxena, Amrita, et al. \"Pharmacokinetics, dose proportionality and permeability of S002-333 and its enantiomers, a potent antithrombotic agent, in rabbits.\" Xenobiotica 45.11 (2015): 1016-1023. Masungi, C., et al. \"Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates.\" Die Pharmazie-An International Journal of Pharmaceutical Sciences 63.3 (2008): 194-199. "],[".html", "Chapter 3  3.1  3.2       3.3     3.4      3.5     3.6 ", " Chapter 3   3.1             ,           .                  ,           .              ,    (free drug hypothesis)  ( 3.1).  3.1:           ,       ,       .   plasma, tissue  microsome      ,                . 3.2              albumin, 1-acid-glycoprotein (AGP), lipoprotein  globulin  .   albumin       50%   ,          .  albumin   8  ,   2       .  AGP, lipoprotein     ,    AGP , lipoprotein ,      , globulin ,     . 3.3             (fluorescence spectroscopy),     (Chromatography and capillary electrophoresis), (Microdialysis),  (Equilibrium Dialysis),  (Ultrafiltration)    (Ultracentrifugation)     .      ,     ,         . 3.3.1  (Equilibrium Dialysis)  (Equilibrium Dialysis)      gold standard  .   3.2         RED (Rapid Equilibrium Dialysis) device     . Plasma chamber (Red)    , Buffer chamber (White) phosphate buffer         ( 4-24) 37  .   Plasma chamber        ,       Buffer chamber    .     Plasma  Buffer chamber     (3.1)  ,  (fraction bound, fb)    (fraction unbound, fu)   .  3.2:  (Equilibrium Dialysis) \\[\\begin{equation} \\% Bound = \\frac{Conc.\\ of\\ \\mathbf{buffer}\\ chamber}{Conc.of\\ \\mathbf{sample}\\ chamber} \\times 100\\ (\\%) \\\\ \\%\\ Unbound = 100 - \\%\\ Bound \\\\ f_u = \\ \\frac{\\%\\ Unbound}{100} \\tag{3.1} \\end{equation}\\]    Plasma Buffer chamber   ,                 .            .  4 ,  24    ,        (recovery)   , Plasma  Buffer chamber     volume    . 3.3.2  (ultrafiltration)   (ultrafiltration)            ,  Buffer                (filtrate)     .  3.3                        .             .      ,         (??)  ,   (non-specific binding, NSB)    (fraction unbound, fu)   .  3.3:  (ultrafiltration)  \\[\\begin{equation} NSB = \\frac{C_{pre} - C_{post}}{C_{pre}} \\\\ f_u = \\frac{F_f}{[(1-NSB) \\times F_e]} \\tag{3.1} \\end{equation}\\] Cpre: initial conc. of compound before filtration in buffer Cpost: recovered conc. of compound after ultrafiltration in buffer Ff: the area ratio of compound after ultrafiltration Fe: the area ratio of compound before ultrafiltration NSB: non-specific binding          ,       .        ,         . 3.3.3  (Ultracentrifugation)   (Ultracentrifugation)   tube   ,    (: 500,000 g, 10-24 )      aqueous layer       ( 3.4).             ,    upper layer ()       aqueous layer      .           ,          .  3.4:  (Ultracentrifugation)  3.4              .       ,        .   90%    ,  highly potent       lipophilicity ,   90%     .   ,  98% high, 90-98% moderate  90%  low       .           .          ,                   .   ,           .    99.9% (fraction bound, fb = 0.999)      99.8% ,  0.1%     ,    (fraction unbound, fu) 0.01 0.02 2         .  (Therapeutic index)               .  , ,     .  ,             (free drug concentration) time profile in vitro   IC50  EC50        , in vitro hERG assay  IC50        .  FDA           R value    .  human PK prediction       IVIVE (In Vitro-In Vivo Extrapolation)  . 3.5     3.5.1   (Low recovery)   ,     .                ,   plastic ware        (non-specific binding, NSB) .                  .                 ,                 .   ,           ( 3.5).       lead optimization  ,       ,     ,         .  3.5:     3.5.2           100   98% (Smith, Dennis A, 2010), FDA  189      99%              ( 3.6).  3.6: US FDA  189   (Liu, Wright, and Hop 2014)       Buffer chamber     , Buffer chamber             .          .      RED device   ,              .   (3.2)  10        . \\[\\begin{equation} \\% Bound = \\frac{Conc.of\\ \\mathbf{buffer}\\ chamber}{Conc.of\\ \\mathbf{sample}\\ chamber} \\times 100(\\%) \\\\ \\% Unbound = 100 - \\% Bound \\\\ f_{u\\ 10\\%} = \\ \\frac{\\%_{unbound}}{100} \\\\ f_{u\\ 100\\%} = \\ \\frac{{\\ \\ \\ f}_{u\\ 10\\%}}{10\\ - 9*f_{u\\ 10\\%}} \\tag{3.2} \\end{equation}\\]              (TRANSIL High Sensitivity Binding Kit3)  ,           . 3.6   ADME : Physicochemical properties         .              .   , , ,  PK       ,    . ,       .  (:          .) Tonika; Gan, Liang-Shang. Plasma protein binding: From discovery to development. Journal of Pharmaceutical Sciences, 102(9), 29532994, 2013. Van Liempd, Sebastiaan; Morrison, Denise; Sysmans, Leen; Nelis, Paul; Mortishire-Smith, Russell. Development and Validation of a Higher-Throughput Equilibrium Dialysis Assay for Plasma Protein Binding. Journal of Laboratory Automation, 16(1), 5667, 2011. Li Di; John P. Umland; Patrick E. Trapa; Tristan S. Maurer. Impact of recovery on fraction unbound using equilibrium dialysis. 101(3), 13271335, 2012. Liu, Xingrong; Wright, Matthew; Hop, Cornelis E. C. A. Rational Use of Plasma Protein and Tissue Binding Data in Drug Design. Journal of Medicinal Chemistry, 57(20), 82388248, 2014. Buscher, Brigitte; Laakso, Sirpa; Mascher, Hermann; Pusecker, Klaus; Doig, Mira; Dillen, Lieve; Wagner-Redeker, Winfried; Pfeifer, Thomas; Delrat, Pascal; Timmerman, Philip. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum. Bioanalysis, 6(5), 673682, 2014. Edward H. Kerns and Li Di, Drug-like properties: Concepts, Structure Design and Methods. Everything you need to know about ADME, 3rd Edition, Cyprotex  "],["-----.html", "Chapter 4       4.1  4.2   4.3   4.4    4.5       in vitro   4.6   4.7 ", " Chapter 4        4.1           .         ,  (metabolism)   ,     (excretion) .    ,    .    ,     ,     .              .   (first-pass effect) .   (elimination)   ,        . 4.2         ,       (biotransformation)   .  (xenobiotics),   (lipophilic)      ,     (hydrophilic)  ,    .          ,         .  reactive metabolite ( reactive intermediate) ,         ,   .      ( 4.1).    phase II          ,    , phase I      reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI)  .  NAPQI phase II      ,            .  4.1:  . ( NAPQI  , )   phase I  phase II  ,          .  phase I    , ,      ,          ,   .  phase II   glucuronide, sulfate      ,     .  phase I  phase II        ,      phase I   phase II   , phase II   phase I        .       . 4.3    ,    phase I   phase II  . 4.3.1 Phase I  Phase I   , ,       . Phase I      cytochrome P450 (CYP),   . CYP (heme)   (endoplasmic reticulum, ER)  , NADPH O2        ( ). CYP3A4/5    ,   , CYP3A4/5          . CYP   ( 4.2).  40%  (homology)    family ,   55%   subfamily ,    .  specific isoform    CYP  (, isozyme) .  allele number  CYP   . (wild type) ,  *1 ,       *2, *3, *13  .     CYP  CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5,    Food and Drug Administration (FDA)  European Medicines Agency (EMA)      ()     (Studies 2020; Agency 2012).  4.2: CYP   Phase I     flavin-containing monooxygenase (FMO)   . FMO     ,    FMO      . FMO   FMO3   ,   , amphetamine, tamoxifen, clozapine, phenothiothiazine    . FMO1             . Phase I      .  CYP   oxidation, dealkylation, hydroxylation  , CYP  FMO monoamine oxidase (MAO)      .      4.1   .  4.1:    -   Reaction Structural formula Drugs I. CYP-dependent oxidations Aliphatic hydroxylation Barbiturates, cyclosporine, ibuprofen Aromatic hydroxylation Phenytoin, propranolol N-dealkylation Sildenafil, diazepam O-dealkylation Codeine S-oxidation Cimetidine, phenothiazine N-oxidation Quinidine Desulfuration Thiopental Epoxidation Carbamazepine II. CYP-independent oxidations Alcohol dehydrogenation, Aldehyde dehydrogenation Ethanol, pyridoxine Oxidative deamination Histamine, norepinephrine Decarboxylation Levodopa       ,       ( 4.2).         .     esterase (ES)  ester hydrolysis ,    amide hydrolysis, epoxide hydrolysis   .  4.2:    - ,   Reaction Structural formula Drugs I. Reduction Chloramphenicol, methadone, naloxone II. Hydrolysis Aspirin, procaine, lidocaine, indomethacin, irinotecan 4.3.2 Phase II  Phase II      glucuronide, sulfate, acetate, glutathione      .         .    uridine 5'-diphospho-glucuronosyltransferases (UDP-glucuronosyltransferases, UGTs), sulfotransferases (SULTs), N-acetyltransferases (NATs), glutathione S-transferase (GST)  . (glucuronidation) UGT   , UGT UGT1 UGT2 2 family .  bilirubin, irinotecan  SN-38 ( UGT1A1), morphine, efavirenz ( UGT2B7)  .      ,      -glucuronidase            . (sulfation)  (acetylation)  SULT NAT  , acetaminophen isoniazid  SULT NAT   .       4.3   .  4.3:    - Phase II Reaction Structural formula Drugs I. Glucuronidation Diazepam, digoxin, acetaminophen, SN-38, efavirenz II. Acetylation Isoniazid, sulfonamide III. Sulfation Methyldopa IV. Glutathione conjugation Acetaminophen, valproic acid, busulfan 4.4        ,  in vitro           .   in vitro       ,    ,            . 4.4.1 In vitro systems     (intact cell system), (subcellular fractions),  (recombinant enzyme)    . 4.4.1.1 Intact cell systems     ((cryopreserved) primary hepatocytes) .        ,       (abundance) (activity)  ,   (donor)       .           ,         HepG2, HepaRG   . ,               ,       .  phase I   , phase II    ,  (intrinsic clearance, CLint)*   . ,      (transporter)   (active transport)  (CLint,pd, CLint,uptake)   .  (permeability)   , uptake transporter       ,          .   (. Sandwich-cultured hepatocytes)     (CLint,bile)   . 4.4.1.2 Subcellular fraction (subcellular fractions)  homogenate  ,   ( 4.3).      microsome, cytosol, S9 ,      ,     . Microsome CYP  UGT  ,         . Microsome cytosol ,     ,          .       4.4   .  4.3: (subcellular fraction)  4.4:  (subcellular fraction)    4.4.1.3 Recombinant enzyme (recombinant enzyme)      .       (reaction phenotyping study)  . CYP   , UGT , SULT, CES     ,           . ,     ,             ,     CLint  . 4.5       in vitro         in vitro  CLint  Km  Vmax.        . 4.5.1 Substrate-depletion  In vitro        .  4.5 ,      ,        .  , microsome NADPH   ,  ES, carboxylesterase (CES), CYP, FMO    ,  CYP3A4   ,  CYP3A4 . , hepatocyte  ,   ,    .  ,    in vitro system   ,     .  4.5: Substrate-depletion      data () Substrate-depletion  ,        ,     .      , y log   4.5  ,   .   (k),    buffer (mL)    (mg) , CLint   . \\[\\begin{equation} CL_{int} = \\frac{-ln\\frac{[S]_2}{[S]_1}}{t2 - t1 \\text{ (min)}} \\cdot \\frac{V\\text{ (ml)}}{P\\text{ (mg)}} \\tag{4.1} \\end{equation}\\]  ,  Km     .  -  Michaelis -Menten (M-M) kinetic , Km   1, Km   0  . Substrate-depletion       ,  CLint        . ,   ,            Km   ,          .   substrate-depletion  CLint ,    underprediction   . 4.5.2 Metabolite-formation   (LC-MS/MS )      ,        .  4.6, -  M-M kinetic   ,            . Metabolite-formation        , substrate-depletion         ,    Vmax Km   .  , ,        . Metabolite-formation    (major metabolite) ,      ()   ,   metabolite profiling       .  4.6: Metabolite-formation     data () 4.6        .         . 4.6.1 (metabolic stability)           .  microsome ,         . Microsome  ,  cofactor chemical inhibitor   pre-incubation         .        , 37 incubation    tube    tube ()   .  4.4  . G1  buffer ,    buffer chemical degradation   . G2 buffer microsome  , cofactor    ES  CES     . G3 G2 NADPH ,     CYP FMO     . G4 G2 NADPH  UDPGA (+alamethicin) ,  UGT    . G1~G4       ,  , FMO   , G5 G6    . G5 45 30 pre-incubation   microsome  FMO   , G6 CYP  chemical inhibitor SKF525A , CYP     .  4.4:     G1 G2 G3 G4 G5 G6 Buffer O O O O O O Microsomes X O O O O O NADPH X X O X O O UDPGA (+ala- methicin) X X X O X X SKF525A - - - - - O Pre- incubation 37, 5 min 37, 5 min 37, 5 min Ice, 30 min 45, 30 min 37, 5 min   X ES, CES ES, CES, CYP, FMO ES, CES, UGT ES, CES, CYP ES, CES, FMO        4.7    .        ,      ,  4.4 G6   ,          . Substrate-depletion  ,       .   4.4      ,           ,        .  4.7:     () 4.6.2 Reaction phenotyping   Reaction phenotyping   metabolic stability   .        ,      .  ,     CYP    ,   reaction phenotyping   CYP          .   , total in vivo CL      () (i.e., the fraction of drug metabolized by a specific enzyme, fm)   . CYP    total in vivo CL 25%  ,  CYP  (identification)  [Studies (2020)}. Reaction phenotyping  1) recombinant enzymes (i.e. CYP , UGT  ) , 2) enzyme-selective chemical inhibitors or antibodies      ,  FDA 1) 2)     [Studies (2020)}.      metabolic stability     . CYP , UGT , MAO, FMO, CES          , substrate-depletion  metabolite-formation     . Recombinant CYP   reaction phenotyping  ( 4.8, 4.9, 4.10).  4.8 ,  CYP      incubation ,        .     ,      .  4.8      CYP3A4 CYP3A5     .  4.8: Recombinant CYP   reaction phenotyping  (substrate-depletion method). rCYP, recombinant CYP; HLM, human liver microsome   LC-MS/MS   ,  4.9   CYP       .  ,      ,    peak   , y relative intensity .  4.9: Recombinant CYP   reaction phenotyping  (metabolite-formation method) (Yanakakis and Bumpus 2012).  CYP     (relative intensity)   .             .    4.10   .  CYP3A4     M1 M2      ,            Km Vmax   .  ,       (Km, Vmax, CLint),   fm   .    ,    (CLint) ,  in vitro - in vitro extrapolation (IVIVE)  in vivo CL     ISEF  RAF     .  4.10: Recombinant CYP   reaction phenotyping  (metabolite-formation method) (Yanakakis and Bumpus 2012).      4.7    in vitro    .  ,                      .          ,  ,   , PBPK    ,    ,  (.      , )  ,         .  "],["-----.html", "Chapter 5       5.1 ", " Chapter 5        5.1       inhibitor    ,  inhibition      . Inhibition    , Reversible inhibition  Time-dependent inhibition .  inhibition   inhibition assay        ,    DDI prediction    . DDI  ,           . Inhibitior    victim drug   victim drug     ,       . DDI  in vitro ADME study     .   in vitro  DDI  FDA  EMA    .  . Perpetrator(inhibitor  inducer)  victim drug    Victim (substrate) : Drug whose PK is affected Perpetrator : Drug that is affecting PK of victim "],["Induction.html", "Chapter 6       6.1  6.2    6.3        In vitro study ", " Chapter 6        6.1             .              .  (inducer)           .                                 .     capacity  CYP isoform    . CYP isoform           (affinity)  capacity         .               .                          (7~10)       . CYP isoform         .         ,  6.2       ??  Nucleus Receptor         .    CYP isoform   3 Nucleus receptor  .   CYP isoform  AhR (Aryl hydrocarbon receptor) mediated control CYP1A1, CYP1A2, CYP1B1       Nucleus     .     CYP   NADPH reductase, glutathion S-transference, Aldehyde dehydrogenase          CAR (Constitutive androstane receptor) mediated control CYP2B6, CYP2C9, CYP3A4        expression       .             (LC-MS/MS)     (ELISA, LC-MS/MS)                        ,       .             .         Phase I/II      /      .         .      . (ADA)      6.2.1     Receptor                            ,    .                 potential      .        .          .                         . 6.2.2                  turnover model ( ??). turnover model    (6.1)     (Rsyn) (kdeg * Enz(0))    (\\(\\frac{dEnz(t)}{dt}\\)) . ## Error in knitr::include_graphics(&quot;media-07/turnover.png&quot;): Cannot find the file(s): &quot;media-07/turnover.png&quot; \\[\\begin{equation} \\frac{dEnz(t)}{dt} = R{syn} - k{deg} \\cdot Enz(t) \\tag{6.1} \\end{equation}\\]      mRNA       (Rsyn)     .       (E50, Emax)        (6.2)      . \\[\\begin{equation} \\frac{dEnz(t)}{dt} = R{syn} \\cdot (1 + \\frac{E{max}C(t)}{EC{50} + C(t)}) - k{deg} \\cdot Enz(t) \\tag{6.2} \\end{equation}\\] ,  CYP2E1 ,     (kdeg)   . 6.3        In vitro study                  .        assay   96-well plated HHEP  .                3~4   2~3   mRNA  enzyme fold change  . CYP3A4 CYP2C9  CYP2B6         CYP3A4    .            .   3           .    rifampin          .    RT-PCR  vehicle control   mRNA fold change     . mRNA    fold change             CYP1E2           enzyme  .    3      ,        .        (Cmax,u)  30~50   .          3             .  CYP           donor      assay environment   . "],["----.html", "Chapter 7      7.1  7.2    7.3       7.4     7.5 In vitro    7.6 ", " Chapter 7       7.1      7.1 .      .        . ,          ,   .   (passive diffusion) ,     (facilitated diffusion)   . ,      ,  .           ,    .    Solute carrier (SLC) transporter ATP-binding cassette (ABC) transporter .           ,         .  7.1:     7.2        SLC transporter ABC transporter . SLC     (uptake), (Na+)       .  ,            2  ,      (symport)     (antiport) .  ,  ,   SLC    . ABC  SLC  ,    (efflux).       ATP .   ,      .       ,    ADME      7.1  .  7.1:    Gene Aliases Tissue Substrate Inhibitor ABCB1 P-gp, MDR1 intestine, liver, kidney, brain, placenta, adrenal, testes digoxin, fexofenadine, indinavir, vincristine, colchicine, topotecan, paclitaxel, loperamide, doxorubicin, vinblastine ritonavir, cyclosporine, verapamil, erythromycin, ketocoanzole, itraconazole, quinidine, elacridar (GF120918), LY335979, valspodar (PSC833) ABCB4 MDR3 liver digoxin, paclitaxel, vinblastine verapamil, cyclosporine ABCB11 BSEP liver pravastatin, taurocholic acid, bile acids cyclosporine, rifampicin, glibenclamide ABCC1 MRP1 intestine, liver, kidney, brain adefovir, indinavir ABCC2 MRP2, CMOAT intestine, liver, kidney, brain methotrexate, glucuronides, valsartan, indinavir, cisplatin, cyclosporine, delavirdine, efavirenz, emtricitabine ABCC3 MRP3, CMOAT2 intestine, liver, kidney, placenta, adrenal etoposide, methotrexate, tenoposide, glucoronides, fexofenadine delavirdine, efavirenz, emtricitabine ABCC4 MRP4 liver, brain adeforvir, tenofovir, methotrexate, topotecan, furosemide, cAMP, celecoxib, diclofenac ABCC5 MRP5 brain ABCC6 MRP6 liver, kidney cisplatin, daunorubicin ABCG2 BCRP intestine, liver, mammary glands, placenta daunorubicin, doxorubicin, topotecan, rosuvastatin, sulfasalazine, imatinib, methotrexate elacridar (GF120918), gefitinib, fumitremorgin C, novobiocin SLCO1A2 OATP1A2, OATP-A brain, liver, kidney E3S, statins, fexofenadine, bile salts, digoxin, methotrexate naringin, ritonavir, lopinavir, saquinavir, rifampicin SLCO1B1 OATP1B1, OATP- C, OATP2 liver rifampin, rosuvastatin, methotrexate, pravastatin, thyroxine, bilirubin, E17BG, cyclosporine, rifampicin, saquinavir, ritonavir, lopinavir SLCO1B3 OATP1B3, OATP8 liver digoxin, fexofenadine, telmisartan, E17BG, bile acids, statins, rifampicin, cyclosporine, ritonavir, lopinavir SLCO2B1 OATP2B1, OATP-B intestine, liver, kidney, brain E3S, statins, taurocholate, fexofenadine, glyburide rifampicin, cyclosporine SLC10A1 NTCP liver, pancreas rosuvastatin, chlorambucil taurocholate SLC15A1 PEPT1 intestine, kidney gly-sar, cephalexin, amoxicillin, captopril, gly-pro SLC15A2 PEPT2 kidney, brain, lung gly-sar, cephalexin, amoxicillin, captopril, fosinopril, zofenopril SLC22A1 OCT1 liver, intestine tetraethylammonium, oxaliplatin, metformin, N-methylpyridinium disopyramide, disopyraminde, quinidine, ritonavir, verapamil SLC22A2 OCT2 kidney, brain tetraethylammonium, oxaliplatin, metformin, N-methylpyridinium, pindolol, cimetidine, cetirizine, testosterone, quinine SLC22A4 OCTN1 kidney, muscle, lung quinidine, verapamil, ipatriopium SLC22A5 OCTN2 kidney, muscle, lung quinidine, verapamil, ipatriopium SLC22A6 OAT1 kidney, brain para-aminohippurate, ciprofloxacine, acyclovir, adefovir, methotrexate, probenecid, cefadroxil, novobiocin SLC22A8 OAT3 kidney, brain E3S, NSAIDs, cefaclor, furosemide, bumetanide probenecid, novobiocin SLC47A1 MATE1 kidney, liver, muscle metformine, N-methylpyridinium, quinidine, cimetidine, procainamide SLC47A2 MATE2-K kidney metformine, N-methylpyridinium, quinidine, cimetidine, procainamide  7.2         ,  ADME  .   breast cancer resistant protein (BCRP), P-glycoprotein (P-gp), multidrug resistance-related protein 2 (MRP2)  efflux ,  (enterocyte)         ,          ,         . Organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP2B1   uptake ,      .   HMG CoA reductase   OATP    ,         . ,    SLC           .  ADME        .  7.2:       (Brouwer et al. 2013) 7.2.1 MDR1 BCRP Efflux  MDR1 (P-gp) BCRP , ,       .  ,      ,    ,     ,      ,   . ,  lumen   MDR1 BCRP  intestinal epithelia luminal side    .    , 1)   ,       2) P-gp BCRP     efflux  ,     . , P-gp    CYP3A4     .  ,   ,      ,     CYP3A4    . ,   50% MDR1     ,   MDR1   ,   .  (blood-brain barrier, BBB)   efflux  brain capillary endothelial cell  MDR1 BCRP  .         MDR1  BCRP  ,              .  , in vitro     , in vivo            . 7.2.2 OATPs OATPs    uptake .      OATP  sinusoidal membrane   OATP1B1, OATP1B3, OATP2B1,    uptake,        ( 7.3). , OATP1B1  (genetic polymorphism) . OATP1B1    HMG-CoA reductase   . OATP1B1 *15 allele    wild-type *1a  *1b allele   pravastatin rosuvastatin AUC  85%, 252%  (Nishizato et al. 2003; Lee et al. 2005).                ,       .  7.3:     7.2.3 MRPs MRPs    efflux  , , ,   .  MRP2 intestinal epithelium apical membrane ,    lumen . ,  MRP2 canalicular membrane ,      , MRP3, MRP4 sinusoidal membrane .  (conjugated bile acids) MPR   ,  MRP2   , MRP3  MRP4   .   , MRP2  , MRP2    , (hyperbilirubinemia)   ,  .  glucuronidation  glutathione conjugate ,  MRP      , in vitro     .   brush-border (apical) membrane MRP2  ,      . 7.2.4 BSEP Bile salt export pump (BSEP)       canalicular membrane     ( 7-3).   BSEP ,   ,      , MRP2      , cholestatic liver disease  , drug-induced liver injury (DILI)   .  , European Medicine Agency (EMA)   Transport Consortium   in vitro BSEP    . (Agency 2012; kenna2020sc1?; zamek2018transporters?) 7.2.5 MATEs Multidrug and toxin extrusion (MATE)    canalicular membrane (MATE1)  proximal tubule cells brush-border membrane (MATE1, MATE2-K)  efflux  ( 7.4).  cationic  zwitter   ,     .  7.4:  proximal tubule cell    7.3       In vitro transporter assay          ,          . ,    ,            .                 .        .  7.5    . (varma2015predicting?) \\[ {CL}_{int,organ} = \\ \\frac{({PS}_{\\inf}\\ + {PS}_{pd})}{{PS}_{\\inf} + {PS}_{pd} + {CL}_{int,met} + {CL}_{int,exc}} \\cdot {(CL}_{int,met} + {CL}_{int,exc}) \\]  7.5:      7.3.1     (high passive permeability)    ,    (Cu)   . ,            ,   (CLint,organ)  (CLint,met)   (CLint,exc) .   PSinf PSeff        (transporter-media-07ted sinusoidal influx clearance)       (transporter-media-07ted sinusoidal efflux clearance) , PSpd  (passive diffusion clearance) . \\[ C_{u,\\ intracellular} = \\ C_{u,\\ extracellular} \\\\ {CL}_{int,organ} = \\ {CL}_{int,met} + \\ {CL}_{int,exc} \\] 7.3.2     (low passive permeability)    ,               .   ,          ,         . \\[ C_{u,\\ intracellular} \\neq \\ C_{u,\\ extracellular} \\\\ {If,\\ (CL}_{int,met} + \\ {CL}_{int,exc}) \\gg \\left( {PS}_{pd} + {PS}_{eff} \\right)\\ then, \\\\ {CL}_{int,organ} = {PS}_{pd} + {PS}_{\\inf} \\] 7.4           .          , , ,    ,      target            . 7.4.1 Sitagliptin  cyclosporin Sitagliptin  cyclosporin      . Sitagliptin 100 mg cyclosporin 600 mg    , sitagliptin Cmax AUC  1.68  1.29  ( 7.6) (krishna2007effect?). Sitagliptin     cyclosporin efflux  MDR1 , sitagliptin   ,   cyclosporine    CYP3A4 , sitagliptin  . ,          ,             ,      .  7.6: Sitagliptin cyclosporine  (krishna2007effect?) 7.4.2 Fimasartan  ketoconazole/rifampicin  sitagliptin  cyclosporin   . Fimasartan OATP1B1/1B3   , CYP3A4  . CYP3A4   ketoconazole  rifampicin fimasartan       (kim2013increased?).  ketoconazole rifampicin fimasartan 240 mg    , ketoconazole fimasartan Cmax  AUC  2.47  2.03 , rifampicin fimasartan Cmax  AUC  10.33  4.60 . ( 7.7 Rifampicin ,  CYP3A4   , OATP1B1  . , rifampicin   OATP1B1 , fimasartan   ,   fimasartan      Cmax  10  .   CYP3A4  , AUC  Cmax   . , rifampicin  , fimasartan t1/2 0.26   ( 7.8) OATP1B1  CYP3A4   ,  fimasartan   .  7.7: Fimasartan ketoconazole/rifampicin  (kim2013increased?)  7.8: Fimasartan ketoconazole/rifampicin  (kim2013increased?) 7.4.3 Cerivastatin  gemfibrozil Cerivastatin      2001   ,     . , cerivastatin  gemfibrozil              . Gemfibrozil   gemfibrozil-glucuronide OTAP1B1 ,   CYP2C8 . , gemfibrozil-glucuronide CYP2C8      (ogilvie2006glucuronidation?). Cerivastatin OATP1B1 , CYP2C8(61%) CYP3A4(37%) . Gemfibrozil   , gemfibrozil  gemfibrozil-glucuronide OATP1B1 CYP2C8  , cerivastatin Cmax AUC  2.5 4.36 (backman2002gemfibrozil?). ( 7.9)  7.9: Cerivastatin-gemfibrozil . Cerivastatin gemfibrozil     () cerivastatin-gemfibrozil   () (backman2002gemfibrozil?) 7.4.4 Metformin  cimetidine Metformin  cimetidine   .    ADME           , metformin  cimetidine     . Cimetidine  metformin   OCT2 MATE1/2-k , metformin   (burt2016metformin?).  , metformin Cmax AUC cimetidine    1.5  1.6 . (wang2007oct2?) ( 7.10)  7.10: Metformin  cimetidine . Metformin  cimetidine    (burt2016metformin?) () metformin cimetidine      (wang2007oct2?) () 7.5 In vitro    In vitro        .   in vitro  ,     gold standard     ,       .       vesicle systems,    (transfected cell lines),  .       ,   . 7.5.1 Vesicular assays Vesicular assays ATP  ABC    , ATPase assay . Efflux                 , ,       uptake           , whole-cell system  efflux      .   vesicular assay   .  7-10 , ABC       (right-side-out)   (inside-out) membrane vesicles .   inside-out membrane vesicle ATP  vehicle     . Inside-out vesicle    ABC (efflux)           , vesicle    ATP  vesicle  .  ,      efflux      . ,    ,    , intact cell system         .   ,  ABC(efflux)    ,   vesicle  ,     .  7.11: (Transfected) Cell lines     , HEK293, LLC-PK1, MDCK, CHO    . HEK293 CHO     ,      uptake    . , LLC-PK1 MDCK     (tight polarized cell monolayers)    , efflux    . Xenopus laevis oocytes    ,            ,    . , oocyte    in vivo PK  (in vitro-in vivo extrapolation, IVIVE)    . 7.5.1.1 Uptake studies using recombinant cell lines     uptake    , incubation  10    .    (wild-type cells)  ,       , uptake     ,   uptake   . ,        ,     .  uptake            ,           .     , incubation  10  ,   uptake   . 7.5.1.2 Bidirectional transport systems Efflux       (polarized cell monolayers)    (bidirectional transport assays)  .  7-11    apical (A)  basolateral (B)  ,  A   , A B     (A-B transport),   B  , B A     (B-A transport)   .    (apparent permeability, Papp) .      efflux   efflux     B-A/A-B    . , B-A/A-B  2 ,   efflux   .  ,  efflux  P-gp  BCRP     ,  (passive transport)   Papp , efflux    ,     Papp   . Papp    . \\[ P_{app} = \\ \\frac{Volume\\ of\\ receptor\\ chamber\\ (mL)\\ }{Membrane\\ area\\ ({cm}^{2}) \\times \\ {Concentration}_{initial}(\\mu M)}\\ \\times \\ \\frac{\\mathrm{\\Delta}\\ Concentration\\ (\\mu M)\\ }{\\mathrm{\\Delta}\\ time\\ (s)} \\]       CaCO-2, MDCKII, LLC-PK1  . CaCO-2 ,        2~3  ,  efflux    ,  efflux       . , MDCKII LLC-PK1    (MDCKII: 3, LLC-PK1: 4~6),  efflux   , efflux       .  7.3 CaCO-2    Papp  . (test) CaCO-2   Papp . B-A/A-B  22.4 test efflux     . P-gp   Zosuquidar test   , B-A/A-B  5.89 , BCRP   Ko143    B-A/A-B  test    .    test efflux , , P-gp     .  .. CaCO-2   Papp    7.5.2 Sandwich-cultured hepatocytes   7-12     (Sandwich-cultured hepatocytes, SCH) ,     polarization, canalicular system  .        6~7    . SCH ,             uptake  ,      .    uptake     SCH  ,  2       .        .    ,    (amount)   ,    Concentrationmedium . \\[ {CL}_{uptake} = \\ \\frac{\\mathrm{\\Delta}\\ Accumulation\\ }{\\mathrm{\\Delta}\\ time \\times \\ {Concentration}_{medium}} \\] ,         SCH incubation,  7-12 (), canalicular system tight junction  .           ,          ,       .     . Accumulationstd      , AccumulationCa2+free          . \\[ {CL}_{bile,\\ int} = \\ \\frac{{Accumulation}_{Std} - {Accumulation}_{{Ca}^{2 +}free}\\ }{{AUC}_{cell}} \\] 7.6            ,    in vitro Papp        kinetic parameter   .          ,             . In vitro   in vivo   ,          . ,       well-stirred model perfusion-limited              .                   (Varma et al. 2017).   CLuptake, CLefflux, CLPD, CLint  sinusoidal uptake   , sinusoidal efflux   ,  ,     , Qh, fB, Eh    ,   ,  extraction ratio . \\[ {CL}_{int,h} = \\ \\frac{{(CL}_{uptake} + {CL}_{PD})\\ \\cdot \\ {CL}_{int}}{{(CL}_{efflux} + {CL}_{PD} + {CL}_{int})} \\\\ {CL}_{h} = \\ Q_{h} \\cdot \\frac{f_{B} \\cdot {(CL}_{uptake} + {CL}_{PD})\\ \\cdot \\ {CL}_{int}}{{Q_{h} \\cdot (CL}_{efflux} + {CL}_{PD} + {CL}_{int}) + \\ f_{B} \\cdot {(CL}_{uptake} + {CL}_{PD})\\ \\cdot \\ {CL}_{int}\\ } = \\ Q_{h} \\cdot E_{h} \\]                      . ,   ,    BBB  , efflux      .    PBPK                 ,      ,          kinetic parameter (Jmax, Km, CL, CLefflux, CLpd )    .  Backman, J. T., C. Kyrklund, M. Neuvonen, and P. J. Neuvonen. 2002. 'Gemfibrozil greatly increases plasma concentrations of cerivastatin', Clin Pharmacol Ther, 72: 685-91. Brouwer, K. L., D. Keppler, K. A. Hoffmaster, D. A. Bow, Y. Cheng, Y. Lai, J. E. Palm, B. Stieger, R. Evers, and Consortium International Transporter. 2013. 'In vitro methods to support transporter evaluation in drug discovery and development', Clin Pharmacol Ther, 94: 95-112. Burt, H. J., S. Neuhoff, L. Almond, L. Gaohua, M. D. Harwood, M. Jamei, A. Rostami-Hodjegan, G. T. Tucker, and K. Rowland-Yeo. 2016. 'Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter media-07ted drug-drug interactions', Eur J Pharm Sci, 88: 70-82. International Transporter, Consortium, K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski, and L. Zhang. 2010. 'Membrane transporters in drug development', Nat Rev Drug Discov, 9: 215-36. Kenna, Gerry. 2020. 'SC1. 4-Can BSEP inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective', Drug Metabolism and Pharmacokinetics, 35: S1-S2. Kim, Jung Won, SoJeong Yi, TaeEun Kim, Kyoung Soo Lim, Seo Hyun Yoon, JooYoun Cho, Min Goo Lee, ImSook Song, SangGoo Shin, and InJin Jang. 2013. 'Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin', The Journal of clinical pharmacology, 53: 75-81. Kim, S. J., K. Toshimoto, Y. Yao, T. Yoshikado, and Y. Sugiyama. 2017. 'Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data', J Pharm Sci, 106: 2715-26. Krishna, Rajesh, Arthur Bergman, Patrick Larson, Josee Cote, Kenneth Lasseter, Stacey Dilzer, Amy Wang, Wei Zeng, Li Chen, and John Wagner. 2007. 'Effect of a single cyclosporine dose on the singledose pharmacokinetics of sitagliptin (MK0431), a dipeptidyl peptidase4 inhibitor, in healthy male subjects', The Journal of clinical pharmacology, 47: 165-74. Lee, E., S. Ryan, B. Birmingham, J. Zalikowski, R. March, H. Ambrose, R. Moore, C. Lee, Y. Chen, and D. Schneck. 2005. 'Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment', Clin Pharmacol Ther, 78: 330-41. Nishizato, Y., I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama. 2003. 'Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics', Clin Pharmacol Ther, 73: 554-65. Ogilvie, B. W., D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson. 2006. 'Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions', Drug Metab Dispos, 34: 191-7. Varma, M. V., A. F. El-Kattan, B. Feng, S. J. Steyn, T. S. Maurer, D. O. Scott, A. D. Rodrigues, and L. M. Tremaine. 2017. 'Extended Clearance Classification System (ECCS) informed approach for evaluating investigational drugs as substrates of drug transporters', Clin Pharmacol Ther, 102: 33-36. Varma, M. V., S. J. Steyn, C. Allerton, and A. F. El-Kattan. 2015. 'Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)', Pharm Res, 32: 3785-802. Wang, Z. J., O. Q. Yin, B. Tomlinson, and M. S. Chow. 2008. 'OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine', Pharmacogenet Genomics, 18: 637-45. ZamekGliszczynski, Maciej J, Mitchell E Taub, Paresh P Chothe, Xiaoyan Chu, Kathleen M Giacomini, Richard B Kim, Adrian S Ray, Sophie L Stocker, Jashvant D Unadkat, and Matthias B Wittwer. 2018. 'Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance', Clinical Pharmacology &amp; Therapeutics, 104: 890-99. (article?){burt2016metformin, title={Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drugdrug interactions}, author={Burt, HJ and Neuhoff, Sybille and Almond, L and Gaohua, L and Harwood, MD and Jamei, Masoud and Rostami-Hodjegan, A and Tucker, GT and Rowland-Yeo, K}, journal={European Journal of Pharmaceutical Sciences}, volume={88}, pages={7082}, year={2016}, publisher={Elsevier} } (article?){ogilvie2006glucuronidation, title={Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions}, author={Ogilvie, Brian W and Zhang, Donglu and Li, Wenying and Rodrigues, A David and Gipson, Amy E and Holsapple, Jeff and Toren, Paul and Parkinson, Andrew}, journal={Drug Metabolism and Disposition}, volume={34}, number={1}, pages={191197}, year={2006}, publisher={ASPET} } (article?){backman2002gemfibrozil, title={Gemfibrozil greatly increases plasma concentrations of cerivastatin}, author={Backman, Janne T and Kyrklund, Carl and Neuvonen, Mikko and Neuvonen, Pertti J}, journal={Clinical Pharmacology &amp; Therapeutics}, volume={72}, number={6}, pages={685691}, year={2002}, publisher={Wiley Online Library} } (article?){kim2013increased, title={Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin}, author={Kim, Jung Won and Yi, SoJeong and Kim, Tae-Eun and Lim, Kyoung Soo and Yoon, Seo Hyun and Cho, Joo-Youn and Lee, Min Goo and Song, Im-Sook and Shin, Sang-Goo and Jang, In-Jin and others}, journal={The Journal of Clinical Pharmacology}, volume={53}, number={1}, pages={7581}, year={2013}, publisher={Wiley Online Library} } (article?){kim2017quantitative, title={Quantitative analysis of complex drugdrug interactions between repaglinide and cyclosporin a/gemfibrozil using physiologically based pharmacokinetic models with in vitro transporter/enzyme inhibition data}, author={Kim, Soo-Jin and Toshimoto, Kota and Yao, Yoshiaki and Yoshikado, Takashi and Sugiyama, Yuichi}, journal={Journal of Pharmaceutical Sciences}, volume={106}, number={9}, pages={27152726}, year={2017}, publisher={Elsevier} } (article?){varma2015predicting, title={Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS)}, author={Varma, Manthena V and Steyn, Stefanus J and Allerton, Charlotte and El-Kattan, Ayman F}, journal={Pharmaceutical research}, volume={32}, number={12}, pages={37853802}, year={2015}, publisher={Springer} } (article?){kenna2020sc1, title={SC1. 4-Can BSEP inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective}, author={Kenna, Gerry}, journal={Drug Metabolism and Pharmacokinetics}, volume={35}, number={1}, pages={S1S2}, year={2020}, publisher={Elsevier BV} } (article?){zamek2018transporters, title={Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance}, author={Zamek-Gliszczynski, Maciej J and Taub, Mitchell E and Chothe, Paresh P and Chu, Xiaoyan and Giacomini, Kathleen M and Kim, Richard B and Ray, Adrian S and Stocker, Sophie L and Unadkat, Jashvant D and Wittwer, Matthias B and others}, journal={Clinical Pharmacology &amp; Therapeutics}, volume={104}, number={5}, pages={890899}, year={2018}, publisher={Wiley Online Library} } (article?){krishna2007effect, title={Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects}, author={Krishna, Rajesh and Bergman, Arthur and Larson, Patrick and Cote, Josee and Lasseter, Kenneth and Dilzer, Stacey and Wang, Amy and Zeng, Wei and Chen, Li and Wagner, John and others}, journal={The Journal of clinical pharmacology}, volume={47}, number={2}, pages={165174}, year={2007}, publisher={Wiley Online Library} }  "],["translation.html", "Chapter 8 Translation 8.1  8.2 (F)  8.3    8.4 Vd  8.5 CL  8.6    translation 8.7    ", " Chapter 8 Translation  8.1  In vitro, in vivo   PK, PD    translation              . In vitro ADME            .                 CL, Vd, ka, F       .            , in vitro ADME          . In vitro                         .   3    in vivo PK  allometry   PK        in vitro    in vivo           .       PK                . In vitro ADME        -  (drug-drug interaction, DDI)  .        ,         PK  ,           in vitro    PBPK    .         DDI              .     (tutorial) 3               .  Transl Clin Pharmacol. 2020 Sep;28(3):126-135 (Yim, Choi, and Bae 2020) 4  Transl Clin Pharmacol. 2020 Dec;28(4):169-174 (Yim and Choi 2020) 5  Transl Clin Pharmacol. 2021 Jun;29(2):78-87 (Yim, Bae, and Choi 2021) 6    PK             .  in vitro, in vivo      PK                      1         . ,     PK          . 8.2 (F)  F F = Fa · Fg · Fh     . Fh CLh       . 8.2.1 Fa  Fa             .     ,  (pKa)   . Caco-2 (permeability)   Fa     . Fa              . Fa    human jejunal permeability ,            Caco-2    .     Caco-2     human jejunal permeability     Fa  Fa  . ( 8.1) (Sun et al. 2002)      8.1)            Fa          .  Caco-2            .    Caco-2   ,                    . Caco-2                   .           Caco-2         Fa        .  8.1: Caco-2  human jejunal permeability, Fa    (Sun et al. 2002)   polar surface area (PSA) Fa                     PSA Fa          (unpublished data)     . 8.2.2 Fg              .    CYP450  80% 3A4       CLint in vitro    CYP3A4    CYP3A4      .    CLint      CLint    . (     ?) 8.2.3 Fh  Fh   CLh   .  Well-stirred model           . &lt;   chapter   . &gt; 8.3         F         .    1       ka  .    ka     Usansky    Caco-2 , , Vc  . (Usansky and Sinko 2005)         Cmax   Cmax     AUC   1          Cmax     .         Cmax     2    Cmax              1  Cmax           . 1                .          1 ,                         1       .  1                .         1          Cmax             2     .  PK             .               PK                         .          Cmax   (AUC)              .       pH  CYP      PBPK           . 8.4 Vd  8.4.1 PBPK         .   /,               .    (ktp)       ,                fu   Vdss .    fu       fu     . (Yim and Choi 2020)  PBPK  Vdss    ,       Vc, Vp    . 8.4.2 Allometry    allometry 3       2    Vc, Vp, Q (intercompartmental CL)        . Allometry  Vd CL     , CL         .   Vd   allometry  ,     2     , Vd            allometry      .          Vd  PBPK allometry                         .   in vitro   PK      allometry   . 8.5 CL       CL  in vivo     .       CYP          in vitro ,      CYP   in vitro   .       CL .       (Transl Clin Pharmacol. 2021 Jun;29(2):78-87 (Yim, Bae, and Choi 2021) 7)      .      (QHB),  (fuB) intrinsic CL (CLu,int,H)  Well-stirred model   . \\[\\begin{equation} {CL}_{H}(L/h) = \\frac{Q_{HB} \\cdot f_{uB} \\cdot {CL}_{u,int,H}}{Q_{HB} + f_{uB} \\cdot {CL}_{u,int,H}} \\tag{8.1} \\end{equation}\\]    CLu,int,H    (  1)   CLu,int   (1200 )  .  1 CLu,int     (, microsome,  CYP)    ,        ,         .      ADME         raw data         . 8.6    translation in vitro       -    ,              in vitro    .     in vitro                     .           ,      in vtiro     ( rifampin) ( itraconazole)     ,    in vitro  PBPK       .         (rifampin itraconazole )   PBPK       AUC, Cmax    PBPK         . 8.7        in vitro        fu          .              99.9%    (, fu 0.1% ) FDA     fu 0.1%   .  in vitro                 fu = 1    .    free drug hypothesis    (Cu,ss) in vitro     IC50, Km, EC50         .           discovery            .     .    30~40% fu 0.1, 0.01  5~10%   . (Liu, Chen, and ECA Hop 2011) 65          Cu,ss   in vitro  (IC50, Km, EC50) (ratio)       Cu,ss IC50    69% . ( 8.2) (Yim 2019)  8.2: In vitro   potency(IC50, EC50 )      Cu,ss . (Yim 2019)           statin      (PPIs)           . , in vitro   in vivo          ,   in vitro      .           , in vitro          PK     .  "],[".html", "", "  "],["404.html", "Page not found", " Page not found The page you requested cannot be found (perhaps it was moved or renamed). You may want to try searching to find the page's new location, or use the table of contents to find the page you are looking for. "]]
